Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
New prescription drug price hikes hit Black patients hard
Prices for prescription pharmaceutical drugs have skyrocketed, disproportionately making them harder for people of color to afford, a new...
-
CDC strengthens advice for boosters as omicron variant spreads globally
All adults should get Covid-19 booster shots when they’re eligible, the Centers for Disease Control and Prevention said Monday,...
-
Tainted water and viruses put Gaza residents, especially kids, at further risk
Clean drinking water is running out in Gaza, furthering an already catastrophic situation. After Hamas’ surprise terrorist attack on...
-
More addictive and harder to quit: Health groups want Black menthol smokers to know support groups can help
As the Biden administration moves closer to banning menthol cigarettes and flavored cigars, major health organizations are pushing to...
-
Elon Musk’s brain implant company Neuralink announces FDA approval of in-human clinical study
Neuralink, the neurotech startup co-founded by Elon Musk, announced Thursday it has received approval from the Food and Drug Administration...
-
CDC arrives in Ohio town to investigate health risks from toxic train derailment
The CDC has arrived in East Palestine, Ohio — three weeks after a train derailment spewed toxic, cancer-causing fumes...
-
Covid crisis reaches Nepal with a surge in cases and hospitalizations
As Covid-19 ravages India, there’s new fear that neighboring Nepal is starting to suffer a similar fate. Cases have...
-
From industrial giant to Covid hotspot: London suburb’s past haunts pandemic response
LONDON — The town of Dagenham was once a thriving symbol of modern Britain. Lines of row houses sprang...
Recent Comments